Return to search

Diminui??o da express?o dos receptores de melatonina MT1 e MT2 em ?reas especificas do sistema nervoso central de roedores submetidos a um tratamento cr?nico com Reserpina

Submitted by Automa??o e Estat?stica (sst@bczm.ufrn.br) on 2017-12-04T20:41:48Z
No. of bitstreams: 1
KayoDiogenesDeAzevedoSilva_DISSERT.pdf: 2312119 bytes, checksum: 0a5f0d4a0645de7bdb4ab990bbb4f59d (MD5) / Approved for entry into archive by Arlan Eloi Leite Silva (eloihistoriador@yahoo.com.br) on 2017-12-07T20:45:07Z (GMT) No. of bitstreams: 1
KayoDiogenesDeAzevedoSilva_DISSERT.pdf: 2312119 bytes, checksum: 0a5f0d4a0645de7bdb4ab990bbb4f59d (MD5) / Made available in DSpace on 2017-12-07T20:45:07Z (GMT). No. of bitstreams: 1
KayoDiogenesDeAzevedoSilva_DISSERT.pdf: 2312119 bytes, checksum: 0a5f0d4a0645de7bdb4ab990bbb4f59d (MD5)
Previous issue date: 2017-07-31 / A doen?a de Parkinson (DP) ? uma patologia neurodegenerativa que acomete
principalmente indiv?duos do sexo masculino com o avan?ar da idade. A DP se
caracteriza por diversos sintomas motores como tremores, bradicinesia, rigidez
e altera??es posturais. Al?m destes, sintomas cognitivos como d?ficits de
aten??o e mem?ria, dem?ncia e altera??es de humor tamb?m est?o presentes.
? poss?vel perceber marcada mudan?a na arquitetura do sono de pacientes
com DP. O horm?nio melatonina sintetizado principalmente pela gl?ndula
pineal localizada no Epit?lamo ? considerado um dos horm?nios que induzem a
fase de sono dos organismos. Sua a??o ocorre ap?s se ligar a receptores
espec?ficos, MT1 e MT2. No presente estudo foram utilizados 15 ratos machos
de meia idade (10 meses) da esp?cie Wistar, divididos em dois grupos
denominados de Controle (CTR) e Reserpina (RES). Esses animais foram
submetidos a um protocolo cr?nico de 20 inje??es de reserpina, com o intuito
de criar sintomatologias semelhantes a DP. Durante o protocolo experimental
os animais foram avaliados atrav?s de teste de catalepsia. Com o fim do
tratamento os animais foram sacrificados e submetidos a procedimento
imunistoquimico para identifica??o dos receptores MT1 e MT2 em 5 ?reas do
sistema nervoso central relacionadas diretamente com o ciclo do sono e com
sintomas mais evidentes da DP, sendo elas, NE, NSQ, VLPO, SN e ZSPV.
Nossos resultados mostraram que durante o per?odo de tratamento os animais
do grupo reserpina apresentaram consider?vel e progressivo d?ficits motores
que se acentuaram nos dias sete, oito, nove e dez de inje??es. Nossas
analises imunoistoqu?micas mostraram que ocorre significativa redu??o da
express?o de receptores de melatonina nos animais reserpina em todos os
n?cleos avaliados, entretanto, novos estudos s?o necess?rios para uma melhor
compreens?o do real motivo dessa diminui??o de express?o de receptores e
se esta diminui??o tem efeito significativo nas altera??es do sono verificadas
nos pacientes com DP. / Parkinson's disease (PD) is a neurodegenerative disorder that mainly affects
males with advancing age. PD is characterized by several motor symptoms
such as tremors, bradykinesia, stiffness and postural changes. In addition to
these, cognitive symptoms such as attention and memory deficits, dementia
and mood changes are also present. It is also possible to notice a marked
change in the sleep architecture of patients with PD. The hormone melatonin
synthesized mainly by the pineal gland located in the thalamus is considered
one of the hormones that induce the sleep phase of the organisms. Its action
occurs after binding to specific receptors, MT1 and MT2. In the present study,
15 male Wistar rats (10 months) were divided into two groups called Control
(CTR) and Reserpine (RES). These animals were submitted to a chronic
protocol of 20 injections of reserpine, in order to create symptoms similar to PD.
During the experimental protocol the animals were evaluated by catalepsy test.
At the end of the treatment the animals were sacrificed and submitted to an
immunohistochemical procedure to identify the MT1 and MT2 receptors in 5
areas of the central nervous system related directly to the sleep cycle and with
more evident symptoms of PD, VLPO, SN and ZSPV. Our results showed that
during the period of treatment the animals of the reserpine group presented a
considerable and progressive motor deficit that were accentuated on days
seven, eight, nine and ten of injections. Our immunohistochemical analyzes
have shown that there is a significant reduction in the expression of melatonin
receptors in the reserpine animals in all evaluated nuclei, however, new studies
are necessary to better understand the real reason for this decrease in receptor
expression and whether this decrease has a significant effect on Observed in
patients with PD.

Identiferoai:union.ndltd.org:IBICT/oai:repositorio.ufrn.br:123456789/24445
Date31 July 2017
CreatorsSilva, Kayo Di?genes de Azevedo
Contributors05189619400, Oliveira, Francisco Gilberto, 05671426391, Cavalcante, Jeferson de Souza, 70317232487, Engelberth, Rovena Clara Galv?o Janu?rio
PublisherPROGRAMA DE P?S-GRADUA??O EM PSICOBIOLOGIA, UFRN, Brasil
Source SetsIBICT Brazilian ETDs
LanguagePortuguese
Detected LanguageEnglish
Typeinfo:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis
Sourcereponame:Repositório Institucional da UFRN, instname:Universidade Federal do Rio Grande do Norte, instacron:UFRN
Rightsinfo:eu-repo/semantics/openAccess

Page generated in 0.0027 seconds